VIDEO: Tremfya induces increased rates of clinical remission in Crohn’s

VIDEO: Tremfya induces increased rates of clinical remission in Crohn’s

In a video exclusive, Jan Wehkamp, MD, vice president, gastroenterology global disease area leader at Janssen Pharmaceuticals, reported positive long-term data evaluating Tremfya for the treatment of patients with Crohn’s disease.Following previously reported interim results, the phase 2 GALAXI 1 study showed rates of clinical remission increased from 12 to 48 weeks (65%) with comparable safety data. Though not currently approved for the treatment of CD in the U.S., phase 3 trials for Tremfya (guselkumab, Janssen) among patients with moderate to severe CD as well as moderate to severeRead More

Share on facebook
Share on twitter
Share on linkedin